Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer

Daisuke Aoki, Yoh Watanabe, Toshiko Jobo, Kimio Ushijima, Kiyoshi Hasegawa, Nobuyuki Susumu, Nao Suzuki, Rui Aoki, Seiji Isonishi, Satoru Sagae, Bunpei Ishizuka, Toshiharu Kamura, Yasuhiro Udagawa, Hiroshi Hoshiai, Yasuo Ohashi, Kazunori Ochiai, Kiichiro Noda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer. Patients and Methods: Women with surgically resected stage Ic-IV epithelial ovarian cancer were treated with docetaxel 70 mg/m2 and cisplatin 60 mg/m2 every 4 weeks. Results: Ninety women were enrolled of whom 89 (median age, 54 years) received a median of 6 cycles (range 1 to 9). With a median 38 months' follow-up, median progression-free survival was 28 months (95% lower confidence interval, 24 months) in 60 patients with stage III-IV disease. The overall response rate for 20 patients was 45%. Neutropenia was the most common (67% ) grade 3/4 toxicity. Major grade 3/4 nonhaematological toxicities were gastrointestinal toxicities (≤11%) and fatigue (8%). No grade 3/4 neurotoxicity was observed. Conclusion: The combination of docetaxel/cisplatin is a regimen with favourable progression-free survival for ovarian cancer.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalAnticancer Research
Volume29
Issue number2
Publication statusPublished - 2009 Feb

Fingerprint

docetaxel
Ovarian Neoplasms
Cisplatin
Disease-Free Survival
Neutropenia
Fatigue
Confidence Intervals
Safety
Drug Therapy

Keywords

  • Cisplatin
  • Clinical trial
  • Docetaxel
  • Ovarian cancer
  • Progression-free survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aoki, D., Watanabe, Y., Jobo, T., Ushijima, K., Hasegawa, K., Susumu, N., ... Noda, K. (2009). Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. Anticancer Research, 29(2), 561-566.

Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. / Aoki, Daisuke; Watanabe, Yoh; Jobo, Toshiko; Ushijima, Kimio; Hasegawa, Kiyoshi; Susumu, Nobuyuki; Suzuki, Nao; Aoki, Rui; Isonishi, Seiji; Sagae, Satoru; Ishizuka, Bunpei; Kamura, Toshiharu; Udagawa, Yasuhiro; Hoshiai, Hiroshi; Ohashi, Yasuo; Ochiai, Kazunori; Noda, Kiichiro.

In: Anticancer Research, Vol. 29, No. 2, 02.2009, p. 561-566.

Research output: Contribution to journalArticle

Aoki, D, Watanabe, Y, Jobo, T, Ushijima, K, Hasegawa, K, Susumu, N, Suzuki, N, Aoki, R, Isonishi, S, Sagae, S, Ishizuka, B, Kamura, T, Udagawa, Y, Hoshiai, H, Ohashi, Y, Ochiai, K & Noda, K 2009, 'Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer', Anticancer Research, vol. 29, no. 2, pp. 561-566.
Aoki, Daisuke ; Watanabe, Yoh ; Jobo, Toshiko ; Ushijima, Kimio ; Hasegawa, Kiyoshi ; Susumu, Nobuyuki ; Suzuki, Nao ; Aoki, Rui ; Isonishi, Seiji ; Sagae, Satoru ; Ishizuka, Bunpei ; Kamura, Toshiharu ; Udagawa, Yasuhiro ; Hoshiai, Hiroshi ; Ohashi, Yasuo ; Ochiai, Kazunori ; Noda, Kiichiro. / Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. In: Anticancer Research. 2009 ; Vol. 29, No. 2. pp. 561-566.
@article{40fc9e99e0564addb32419e4345f01b4,
title = "Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer",
abstract = "Background: The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer. Patients and Methods: Women with surgically resected stage Ic-IV epithelial ovarian cancer were treated with docetaxel 70 mg/m2 and cisplatin 60 mg/m2 every 4 weeks. Results: Ninety women were enrolled of whom 89 (median age, 54 years) received a median of 6 cycles (range 1 to 9). With a median 38 months' follow-up, median progression-free survival was 28 months (95{\%} lower confidence interval, 24 months) in 60 patients with stage III-IV disease. The overall response rate for 20 patients was 45{\%}. Neutropenia was the most common (67{\%} ) grade 3/4 toxicity. Major grade 3/4 nonhaematological toxicities were gastrointestinal toxicities (≤11{\%}) and fatigue (8{\%}). No grade 3/4 neurotoxicity was observed. Conclusion: The combination of docetaxel/cisplatin is a regimen with favourable progression-free survival for ovarian cancer.",
keywords = "Cisplatin, Clinical trial, Docetaxel, Ovarian cancer, Progression-free survival",
author = "Daisuke Aoki and Yoh Watanabe and Toshiko Jobo and Kimio Ushijima and Kiyoshi Hasegawa and Nobuyuki Susumu and Nao Suzuki and Rui Aoki and Seiji Isonishi and Satoru Sagae and Bunpei Ishizuka and Toshiharu Kamura and Yasuhiro Udagawa and Hiroshi Hoshiai and Yasuo Ohashi and Kazunori Ochiai and Kiichiro Noda",
year = "2009",
month = "2",
language = "English",
volume = "29",
pages = "561--566",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer

AU - Aoki, Daisuke

AU - Watanabe, Yoh

AU - Jobo, Toshiko

AU - Ushijima, Kimio

AU - Hasegawa, Kiyoshi

AU - Susumu, Nobuyuki

AU - Suzuki, Nao

AU - Aoki, Rui

AU - Isonishi, Seiji

AU - Sagae, Satoru

AU - Ishizuka, Bunpei

AU - Kamura, Toshiharu

AU - Udagawa, Yasuhiro

AU - Hoshiai, Hiroshi

AU - Ohashi, Yasuo

AU - Ochiai, Kazunori

AU - Noda, Kiichiro

PY - 2009/2

Y1 - 2009/2

N2 - Background: The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer. Patients and Methods: Women with surgically resected stage Ic-IV epithelial ovarian cancer were treated with docetaxel 70 mg/m2 and cisplatin 60 mg/m2 every 4 weeks. Results: Ninety women were enrolled of whom 89 (median age, 54 years) received a median of 6 cycles (range 1 to 9). With a median 38 months' follow-up, median progression-free survival was 28 months (95% lower confidence interval, 24 months) in 60 patients with stage III-IV disease. The overall response rate for 20 patients was 45%. Neutropenia was the most common (67% ) grade 3/4 toxicity. Major grade 3/4 nonhaematological toxicities were gastrointestinal toxicities (≤11%) and fatigue (8%). No grade 3/4 neurotoxicity was observed. Conclusion: The combination of docetaxel/cisplatin is a regimen with favourable progression-free survival for ovarian cancer.

AB - Background: The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer. Patients and Methods: Women with surgically resected stage Ic-IV epithelial ovarian cancer were treated with docetaxel 70 mg/m2 and cisplatin 60 mg/m2 every 4 weeks. Results: Ninety women were enrolled of whom 89 (median age, 54 years) received a median of 6 cycles (range 1 to 9). With a median 38 months' follow-up, median progression-free survival was 28 months (95% lower confidence interval, 24 months) in 60 patients with stage III-IV disease. The overall response rate for 20 patients was 45%. Neutropenia was the most common (67% ) grade 3/4 toxicity. Major grade 3/4 nonhaematological toxicities were gastrointestinal toxicities (≤11%) and fatigue (8%). No grade 3/4 neurotoxicity was observed. Conclusion: The combination of docetaxel/cisplatin is a regimen with favourable progression-free survival for ovarian cancer.

KW - Cisplatin

KW - Clinical trial

KW - Docetaxel

KW - Ovarian cancer

KW - Progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=61449166016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449166016&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 561

EP - 566

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -